The Claim
Higher plasma levels of matrix metalloproteinase 1 (MMP1) are associated with reduced odds of mild cognitive impairment at baseline in older adults aged 70–80 at high risk of mobility disability, with those in the highest quartile having approximately 40% lower odds (OR = 0.64, 95% CI: 0.37–1.08) compared to the lowest quartile.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Older adults aged 70–80 at high risk of mobility disability with higher levels of MMP1 in their blood have lower rates of mild cognitive impairment at the time of measurement compared to those with lower levels.
See the scientific wording
Higher plasma levels of matrix metalloproteinase 1 (MMP1) are associated with reduced odds of mild cognitive impairment at baseline in older adults aged 70–80 at high risk of mobility disability, with those in the highest quartile having approximately 40% lower odds (OR = 0.64, 95% CI: 0.37–1.08) compared to the lowest quartile, suggesting MMP1 may have a protective or compensatory role in early cognitive impairment.
Higher levels of MMP1 in the blood break down stiffened collagen in brain tissue, which clears away damaged material and prevents immune cells from becoming overactive. This keeps brain connections healthy and stops memory problems from starting.
What the research says
1 studyOlder adults with more MMP1 in their blood were less likely to have memory problems at the start of the study, suggesting MMP1 might help protect the brain as we age.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.